system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Antigens, Differentiation, T-Lymphocyte, Autoimmunity, CD4-Positive T-Lymphocytes, CD8 Antigens, Cells, Cultured, Cytotoxicity, Immunologic, Endometriosis, Female, Humans, In Vitro Techniques, Interleukin-2, Isoantigens, Keratinocytes, Killer Cells, Natural, Lymphocyte Activation, Phenotype, Recombinant Proteins, T-Lymphocyte Subsets, Tumor Cells, Cultured.
user
Does recombinant interleukin-2 correct in vitro the immunological defect of endometriosis? Context: It has been shown recently that women with endometriosis have several immunological defects. In particular, these patients have a defect in peripheral blood natural killer cell activity and have lost their capacity of recognizing and lysing autologous endometrial cells. We evaluated the effect of recombinant interleukin-2 (rIL-2) on peripheral blood lymphocytes obtained from both healthy donors and endometriosis patients. The generation of a strong cytolytic activity against autologous endometrial cells was obtained from both normal donors and endometriosis patients. Interestingly, these cytolytic cells belong to the T-cell lineage and do not recognize both autologous keratinocytes and allogeneic endometrial cells, thus suggesting a mechanism of specific recognition of autologous cells.
assistant
The capability of restoring cytolytic activity using rIL-2 suggests a new immunotherapeutic approach for the treatment of severe endometriosis. Final Decision: yes